Clinical Trials · NCT02090673
Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 1,711
- Start date
- Feb 2009
- Locations
- 1 site, South Korea
- Primary endpoint
- The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus